2
being free of Enterococcus-like vancomy- REFERENCES 9. Gueimonde, M., Ouwehand, A.C. &
cin-resistant genes. 1. Haarman, M. & Knol, J. (2006). Salminen, S. (2004). Safety of probiot-
As yet, no case of antibiotic resistance Quantitative Real-Time PCR Analysis ics. Scandinavian Journal of Nutrition.
transfer has ever been identified and of Fecal Lactobacillus Species in Infants 48:42-48.
reported for lactic acid bacteria used in Receiving a Prebiotic Infant Formula 10. Mogensen, G., Salminen, S., OBrien,
foods and feed. Applied and Environmental Microbiology. J., Ouwehand, A.C., Holzapfel, W., Shortt,
The antibiotic susceptibility patterns for 72, (4) 2359-2365. C., Fonden, R., Miller, G.D., Donohue, D.,
L. casei Lc-11 are summarised in table 1. 2. Dicks, L.M.T., D Plessis, E.M., Dellaglio, F. Playne, M., Crittenden, R., Salvadori, B. &
& Lauer, E. (1996). Reclassification of Zink, R. (2002). Inventory of microorgan-
Lactobacillus casei Lc-11 antibiogram Lactobacillus casei subsp. casei ATCC 393 isms with a documented history of safe
Amoxicillin S and Lactobacillus rhamnosus ATCC 15820 use in food. Bulletin of the International
Ampicillin S as Lactobacillus zeae nom. rev., designa- Dairy Federation. 377:10-19.
Ceftazidime R tion of ATCC 334 as the neotype of 11. List of taxonomic units proposed for
L. casei subsp. casei, and rejection of the QPS status http://www.efsa.europa.eu/
Chloramphenicol R
name Lactobacillus paracasei. Int. J. Syst. EFSA/Scientific_Opinion/sc_op_ej587_
Ciprofloxacin R
Bacteriol. 46: 337-340. qps_en.pdf.
Clindamycin I
3. Dellaglio, F., Dicks, L.M.T., Du Toit, M. & 12. Delcour, J., Ferain,T., Deghorain,
Cloxacillin I
Torriani, S. (1991). Designation of ATCC M., Palumbo, E. & Hols, P. (1999). T he
Dicloxacillin S 334 in place of ATCC 393 (NCDO 161) biosynthesis and functionality of the cell-
Erythromycin I as the neotype strain of Lactobacillus wall of lactic acid bacteria. Antonie Van
Gentamicin R casei subsp. casei and rejection of the Leeuwenhoek. 76(1-4):159-84.
Imipenem R name Lactobacillus paracasei (Collins et
Kanamycin R al., 1989). Request for an opinion. Int. J.
Neomycin R Syst. Bacteriol. 41: 340-342.
Nitrofurantoin R 4. Dobson, C.M., Chaban,B., Deneer, H.
Penicillin G S & Ziola, B. (2004). Lactobacillus casei,
Polymixin B R Lactobacillus rhamnosus, and Lactobacillus
Rifampicin S zeae isolates identified by sequence
Streptomycin R signature and immunoblot phenotype.
Canadian Journal of Microbiology. 50, (7),
Sulfamethoxazole R
482-488.
Tetracycline R
5. Aguirre, M. & Collins, M.D. (1993).
Trimethoprim R
Lactic acid bacteria and human clinical
Vancomycin R
infections. J. Appl. Bact. 75:95-107.
S = Susceptible (minimum inhibitory
concentration 4g/ml) 6. Gasser, F. (1994). Safety of lactic acid
I = Intermediate (minimum inhibitory bacteria and their occurrence in human
concentration = 8 to 32g/ml)
clinical infections. Bull. Inst. Pasteur.
R = Resistant (minimum inhibitory
concentration 64g/ml) 92:45-67.
Table 1. 7. Salminen, S., von Wright, A., Morelli,
L., Marteau, P., Brassart, D., de Vos,
W.M., Fonden, R., Saxelin, M., Collins, K.,
BENEFIT SUMMARY Mogensen, G., Birkeland, S.-E. & Mattila-
Based on the data generated, the strains Sandholm,T. (1998). Demonstration of
key attributes can be summarised as safety of probiotics-a review. Int. J. Food
follows: Prot. 44:93-106.
L. casei Lc-11 is well suited for intestinal 8. Borriello, S.P., Hammes, W.P., Holzapfel,
survival and functionality W., Marteau, P., Schrezenmeir, J.,Vaara, M.
-- Highly tolerant of acid and bile & Valtonen,V. (2003). Safety of probiotics
-- Adheres strongly to intestinal Caco-2 that contain lactobacilli or bifidobacteria.
cell lines Clin. Infect. Dis. 36:775-780.
-- Inhibits common pathogens
3
Danisco A/S The information contained in this
Edwin Rahrs Vej 38 publication is based on our own
DK-8220 Brabrand, Denmark research and development work
Telephone: +45 89 43 50 00 and is to the best of our knowl-
Telefax: +45 86 25 10 77 edge reliable.
info@danisco.com Users should, however, conduct
www.danisco.com their own tests to determine the
suitability of our products for their
own specific purposes and the
legal status for their intended use
of the product.
Statements contained herein
should not be considered as a
warranty of any kind, expressed
or implied, and no liability is ac-
cepted for the infringement of
any patents.
Regarding Health Claims,
users should conduct their own
legal investigations into national
demands when marketing and
selling a consumer product con-
taining the probiotic described in
this technical memorandum.
01.08